Supplementary Material for: A case: Thrombocytopenia in an EGFR 19 exon-deficient bilateral diffuse LUAD with ARDS treated with ECMO and Osimertinib

Introduction: EGFR-sensitive mutations bilateral-diffuse lung adenocarcinoma (LUAD) complicated with acute respiratory distress syndrome (ARDS)is relatively rare. Whether EGFR-TKI can be simultaneously received when treating with extracorporeal membrane oxygenation (ECMO) and anti-infective therapy in these patients, and what adverse events should be noted?
Case Presentation: We report a case of EGFR 19 exon-deficient bilateral diffuse LUAD complicated with ARDS. When treated with ECMO and anti-infective therapy, the patient received oral Osimertinib anti-tumor therapy simultaneously. The tumor receded, but eventually irreversible thrombocytopenia developed.
Conclusion: For patients with severe lung cancer, anti-tumor efficacy and adverse events should be closely observed during anti-tumor therapy.